Karyopharm Appoints Justin Renz EVP, CFO With Effect From Aug. 18 - Quick Facts

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, announced Friday that it has appointed Justin Renz as executive vice president and chief financial officer, effective August 18. Renz will succeed Paul Brannelly, who served as Karyopharm's SVP, Finance and Administration until August 2014.

Renz will report to Michael Kauffman, Karyopharm's Chief Executive Officer.

Kauffman said, "Justin's strong leadership skills will be key as we continue to mature as a public company and execute on our development strategy for our lead drug candidate, Selinexor (KPT-330), and our other novel compounds."

Kauffman noted that Brannelly was instrumental in Karyopharm's successful IPO and follow-on offering

Renz most recently served as Executive Vice President and Chief Financial Officer at Zalicus Inc., formerly CombinatoRx, Inc. which he joined in 2006. More recently, he was instrumental in the reverse merger and sale of Zalicus to EPIRUS Biopharmaceuticals Inc. Prior to Zalicus, Renz served in senior finance and accounting roles at Serono, Inc. and Coley Pharmaceutical Group, Inc.

Karyopharm shares closed Thursday's trading at $35.48, down $0.83 or 2.29 percent.